{"id":"W2915409618","doi":"10.1158/1538-7445.sabcs15-p4-14-20","title":"Abstract P4-14-20: A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Lapatinib; Tolerability; Internal medicine; Metastatic breast cancer; Pertuzumab; Trastuzumab; Trastuzumab emtansine; Taxane; Capecitabine; Oncology; Context (archaeology); Cancer; Breast cancer; Gastroenterology; Adverse effect; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006761173,0.001127525,0.0009575543,0.0003263735,0.0002930899,0.0006982374,0.0008151609,0.000756682,0.004160326],"category_scores_gemma":[0.0003806723,0.0004197025,0.000562983,0.0002856143,0.0006375773,0.0005283313,0.0002893851,0.002157925,0.000843258],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008788225,"about_ca_system_score_gemma":0.001494697,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001531982,"about_ca_topic_score_gemma":0.003251912,"domain_scores_codex":[0.9998206,0.00005730419,0.00001066589,0.00003725919,0.00002671705,0.00004747872],"domain_scores_gemma":[0.9997506,0.00002388151,0.00003887643,0.00002041515,0.00002006733,0.0001462722],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3842643,0.1464171,0.008945331,0.001363464,0.001375982,0.0006827678,0.0004610479,0.006195968,0.2547464,0.0006475289,0.01135118,0.1835489],"study_design_scores_gemma":[0.2136938,0.7377326,0.01584303,0.00005221079,0.0005300842,0.0006804491,0.00008443565,0.002214122,0.02272834,0.0002639655,0.006136972,0.00004013469],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945427,0.0007293809,0.0004294238,0.0001804547,0.00003807568,0.001180721,0.0008264693,0.00008683477,0.001985873],"genre_scores_gemma":[0.9873267,0.001132961,0.001533629,0.0004421347,0.00006900977,0.001214061,0.002899232,0.00004399423,0.005338351],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004160326,"threshold_uncertainty_score":0.01391762,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1294193937227333,"score_gpt":0.4706418909622964,"score_spread":0.3412224972395631,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}